SUBSCRIBE
SUBSCRIBE

Nick Paul Taylor

Nick is a freelance writer who has been reporting on the global life sciences industry since 2008. With a BSc in biology, Nick writes about the science and business of biopharma and medtech for numerous healthcare publications. He can be reached at nick.paul.taylor@gmail.com or on LinkedIn.

Pictured: GSK's headquarters building in West London
Drug Development
GSK’s Long-Acting Asthma Drug Hits Primary Endpoint in Phase III Trials
Participants experienced fewer asthma attacks when receiving the antibody every six months, GSK said Tuesday, positioning the company to file for approval of the potential blockbuster.
May 21, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: U.S. Capitol Building, Washington DC
Policy
Sanders Warns Weight-Loss Drugs Could Bankrupt US Healthcare System
A Senate health committee report published Wednesday forecasts spending on prescription drugs to hit $1 trillion a year in 2031, unless the prices of GLP-1 medicines such as Novo Nordisk’s Wegovy are cut.
May 16, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Facade of Takeda's office in Massachusetts
Business
Takeda Inks Potential $2.2B Deal for AC Immune’s Alzheimer’s Immunotherapy
Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease candidate that could activate the immune system to clear amyloid beta plaques.
May 13, 2024
 · 
2 min read
 · 
Nick Paul Taylor
AstraZeneca's sign on its office in California
Drug Development
AstraZeneca Invests $140M in Cellectis, Secures 44% Stake in CAR-T Specialist
Cell and gene therapy company Cellectis announced Monday it has completed a $140 million investment from AstraZeneca that extends the biotech’s cash runway into 2026.
May 6, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Novartis headquarters in Basel, Switzerl
Deals
Novartis Buys Mariana Oncology in $1B Acquisition, Bolsters Radiopharma Assets
The Swiss drugmaker is paying $1 billion and committing up to $750 million in milestones for Mariana Oncology’s preclinical cancer pipeline and clinical supply capabilities, the companies announced Thursday.
May 2, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: An hourglass connected by strands of DNA
Drug Development
Prime Medicine Gets FDA Okay for First Trial of Gene Editing Technique
The FDA has cleared a clinical trial of an ex vivo prime editing candidate in patients with a rare disease, Prime Medicine announced Monday. The technique taps CRISPR technology to rewrite defective genes without breaking DNA double helix strands.
April 30, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Illustration of cancer cells being held in the crosshairs of a scope
Deals
Ono to Buy Deciphera for $2.4B, Looks to Expand Cancer Pipeline and US Footprint
Ono Pharmaceutical will pay $25.60 per share in an all-cash deal to buy Deciphera Pharmaceuticals for its potential blockbuster oncology drugs and U.S. sales infrastructure, the companies said Monday.
April 29, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Regeneron logo on a light brown building
Business
Regeneron Pays Mammoth $100M to Access CRISPR Enzymes for AAV Delivery
Regeneron will use Mammoth Biosciences’ tiny Cas enzymes to deliver in vivo CRISPR-based gene editing therapies to tissues and cell types beyond the liver, the companies announced Thursday.
April 25, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Glitchy Human Hand Connecting with Robot
Business
AI-Powered Xaira Launches with $1B, Ex-Genentech Execs Look to Transform R&D
Xaira Therapeutics emerged from stealth on Tuesday with plans to tap the biological equivalent of artificial intelligence image generation tools designed to create molecules that hit hard-to-drug targets.
April 24, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Incyte's logo on its building in Delaware
Deals
Incyte Inks $750M Deal to Buy Escient and Skin Disease Drug Candidates
CEO Hervé Hoppenot said Tuesday on an investor call that Escient Pharmaceuticals’ two lead assets “address large populations with a clear medical need” with a potential multibillion-dollar market opportunity.
April 23, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Boehringer Ingelheim's office in California
Business
Boehringer, Ochre Bio Team in Potential $1B Deal to Develop Regenerative Liver Drugs
Boehringer Ingelheim is paying $35 million in upfront and near-term fees to work with Ochre Bio to identify and validate regenerative targets for metabolic dysfunction-associated steatohepatitis and other chronic liver diseases.
April 22, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: GSK's headquarters in London
Drug Development
GSK Touts Late-Stage Antibiotic Win in Gonorrhea, Long-Term Shingrix Vaccine Data
GSK’s antibiotic eliminated the bacterial cause of gonorrhea in 92.6% of patients in a Phase III study, while its Shingrix vaccine’s efficacy in shingles remained above 70% over 11 years of follow up.
April 17, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Novartis' office building in Marburg, Germany
Drug Development
Novartis Secures Phase III Fabhalta Win in IgAN as FDA Starts Priority Review
Novartis on Monday shared late-stage data for its potential multibillion-dollar drug Fabhalta, in what the company contends is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in IgA nephropathy patients.
April 16, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Roche Diagnostics building in California
Drug Development
Roche Bispecific T Cell Engager Improves Survival in Lymphoma, Teeing up Label Expansion
Roche said Monday that its bispecific T cell engager Columvi improved survival in a Phase III lymphoma trial, clearing the drugmaker to seek a full, expanded label that could drive sales growth.
April 15, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Pictured: Facade of Moderna's building in Massachusetts
Business
Moderna Halts Plans for Kenyan mRNA Vaccine Plant After Taking $1B Financial Hit
Moderna Thursday said it paused plans to build an mRNA manufacturing facility in Kenya to buy time to assess vaccine demand after being hit with $1 billion in losses and write-downs due to canceled orders.
April 11, 2024
 · 
2 min read
 · 
Nick Paul Taylor
Load More